Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H39ClF3N7O7 |
InChIKeyRXNCFKROSBZSCB-LZDHLTRGSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 23 Nov 2022 | |
Neoplasms | Preclinical | China | 23 Nov 2022 |